Digipath, Inc. (DIGP)
Digipath, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Las Vegas, NV, US. The stock last traded at $0.01, up 4.00% on the session, giving a market capitalisation of $1.1M. On trailing twelve-month figures it carries a trailing P/E of -0.96, a net margin of 0.0%. Its beta of 0.42 implies it has historically moved less than the broad market.
Digipath, Inc., with its subsidiaries, offers essential laboratory testing for cannabis and hemp, primarily serving Nevada's licensed medical marijuana enterprises from its base in Las Vegas. Beyond these core analytical services, the company also provides comprehensive support to the broader cannabis industry, including educational programs, professional training, and news coverage. As a dedicated testing laboratory, Digipath analyzes various products such as cannabis, cannabis-infused items, hemp, and other botanical nutraceuticals, catering to cultivators, dispensaries, caregivers, producers, patients, and end-users of these botanical goods. A critical aspect of their operations involves rigorously screening medicinal and recreational cannabis for potential contaminants. This includes checks for residual solvents, moisture content, water activity, and visual integrity, alongside identifying pesticides, a spectrum of heavy metals (like mercury, arsenic, lead, cadmium, chromium, and nickel), biological toxins (including aflatoxin and ocratoxins), and a wide array of microbial contaminants (such as E. coli, salmonella, coliforms, aspergillus, gram-negative bacteria, total aerobic bacteria, mold, and yeast). Digipath, Inc. was established in 2010 and is headquartered in Las Vegas, Nevada.
Digipath, Inc. is most often compared with the following Healthcare names: